Efficacy And Safety Of Anlotinib Combined With Tegafur In The Treatment Of Third-line And Later Advanced Non-small Cell Lung Cancer

Objective:To observe the efficacy and safety of anlotinib combined with tegafur in the treatment of third-line and above advanced non-small cell lung cancer(NCSLC).Methods:This study retrospectively analyzed the data of patients with advanced non-small cell lung cancer(NSCLC)treated with anlotinib or anlotinib combined with tegafur in the Liaoning Cancer Hospital from January 1,2019 to December 31,2020.The SPSS22.0 software was used for statistical analysis of the data,and the count data was expressed as rate(%),using the X2 test;Kaplan-Meier method was used to draw survival curve,Log-rank comparison of survival rates between groups;Cox regression model for multivariate analysis.P <0.05 indicates that the difference is statistically significant.Results:A total of 60 patients were included in this study,30 in the anlotinib group and 30 in the anlotinib combined with tegafur group.The results of the efficacy analysis showed that the objective response rates(ORR)of the anlotinib group and the anlotinib combined with tegafur group were 6.7% and 26.7%,respectively,and the difference was statistically significant(P=0.038);anlotinib The disease control rate(DCR)of the anlotinib combined with tegafur group was 70.0% and 86.7%,respectively,and the difference was not statistically significant(P=0.117).The results of survival analysis showed that the median progression-free survival(m PFS)of the anlotinib group was 3.7 months(95%CI: 2.288-5.112),and the m PFS of the anlotinib combined with tegafur group was 5.2 months(95%CI: 4.044-6.356),the difference was statistically significant(P=0.017).The median overall survival(m OS)of the anlotinib group was 6.7 months(95%CI: 6.040-7.360),and the m OS of the anlotinib combined with tegafur group was 8.1 months(95%CI: 7.184-9.016),the difference was not statistically significant(P=0.087).In terms of the safety of anlotinib combined with tegafur,common adverse reactions include gastrointestinal reactions(50.0%),fatigue(40.0%),bone marrow suppression(30.0%),hypertension(26.7%),and thyroid stimulation Elevated hormones(16.7%),hand-foot syndrome(16.7%),oral mucositis(13.3%).The results of univariate analysis showed that treatment group (P=0.018)and functional status score(PS)(P=0.012)were factors affecting progression-free survival(PFS).The results of multivariate Cox regression analysis showed that treatment group(P=0.021,95%CI: 1.106-3.468)and PS score(P=0.016,95%CI: 1.179-4.868)were independent risk factors affecting PFS.Conclusion:Anlotinib combined with tegafur is effective for the third-line and above treatment of advanced NSCLC.Compared with single agent anlotinib,it can significantly increase the effective rate and prolong the patient’s PFS,and the drug toxicity and side effects are controllable.